Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | C5 | P01031 | 2/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19377140 | 0.91 | ROCK2 (0.46) | ROCK2HSD17B10MTORC5IDH1 | |
| SCHEMBL19377385 | 0.88 | HSD17B10 (0.43) | ROCK2HSD17B10MTORC5IDH1 | |
| SCHEMBL19377382 | 0.79 | HSD17B10 (0.43) | ROCK2HSD17B10MTORC5IDH1 | |
| SCHEMBL19377048 | 0.78 | ROCK2 (0.66) | ROCK2HSD17B10MTORNAMPT | |
| SCHEMBL19377374 | 0.78 | ITGB3 (0.46) | C5 | |
| SCHEMBL19398891 | 0.76 | ACACB (0.42) | C5 | |
| SCHEMBL19377077 | 0.74 | IDH1 (0.52) | ROCK2HSD17B10MTORIDH1NAMPT | |
| SCHEMBL19377040 | 0.74 | IDH1 (0.52) | ROCK2HSD17B10MTORIDH1NAMPT | |
| SCHEMBL24800223 | 0.71 | ITGB3 (0.38) | ROCK2HSD17B10MTOR | |
| SCHEMBL19377210 | 0.70 | HSD17B10 (0.48) | ROCK2HSD17B10MTORIDH1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | claimed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | UTS2R, GHSR, GRPR | ROCK2 4208/4885HSD17B10 2852/4885MTOR 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.